ARTICLE | Clinical News
Lirilumab: Ph I/II CA223-001 data
November 11, 2016 8:30 PM UTC
Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-00...